<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8292">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00841971</url>
  </required_header>
  <id_info>
    <org_study_id>PRO08110001</org_study_id>
    <nct_id>NCT00841971</nct_id>
  </id_info>
  <brief_title>Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients</brief_title>
  <official_title>Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of anidulafungin versus fluconazole for
      the prevention of fungal diseases in liver transplant recipients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A number of well characterized risk factors have been shown to portend a high risk of
      opportunistic mycoses after liver transplantation.

      Retransplantation and renal failure are amongst the most significant risk factors for
      invasive fungal infections in these patients.

      Most Invasive fungal infections in these high-risk patients occur within the first month
      posttransplant.

      Studies utilizing universal prophylaxis have primarily employed fluconazole. A recent
      meta-analysis of prophylactic trials documented a beneficial effect on morbidity and
      attributable mortality, but an emergence of infections due to non-albicans Candida spp. in
      patients receiving prophylaxis.

      The availability of echinocandins has led to an expanded armamentarium of antifungal drugs
      with a potentially promising role as agents for targeted prophylaxis for invasive fungal
      infections in high-risk liver transplant recipients. Anidulafungin is unique amongst
      echinocandins in that it is eliminated from the body almost exclusively through
      biotransformation by slow non-enzymatic degradation in the blood, without hepatic metabolism
      or renal elimination. Anidulafungin has demonstrated good safety profile. We hypothesize
      that anidulafungin will be more effective and a better tolerated antifungal prophylactic
      agent in this setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Frequency of Fungal Infection</measure>
    <time_frame>90 days post enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Additional Antifungal Therapy</measure>
    <time_frame>90 days post enrollment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Mycoses</condition>
  <condition>Fungemia</condition>
  <condition>Central Nervous System Fungal Infections</condition>
  <condition>Lung Diseases, Fungal</condition>
  <arm_group>
    <arm_group_label>anidulafungin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anti-fungal agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anti-fungal agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anidulafungin</intervention_name>
    <description>200 mg IV loading dose followed by 100 mg qd for 21 days</description>
    <arm_group_label>anidulafungin</arm_group_label>
    <other_name>Eraxis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>400 mg IV for 21 days</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>DIFLUCAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver transplant recipient at increased risk for infection increased risk include any
             of the following:

          -  retransplantation

          -  renal replacement therapy (dialysis),

          -  post transplant abdominal surgery (within 21days)

          -  receipt of corticosteroids for greater than 14 days within the 4 weeks -preceding
             transplant

          -  ICU care for greater than 48 hours at the time of transplantation

          -  colonization with Candida sps within 4 weeks of transplantation

          -  requirement of 15 units or greater of packed red cell transfusions

          -  Intraoperative time exceeding 6 hours

        Exclusion Criteria:

          -  Hypersensitivity to azole or echinocandin antifungal agents

          -  receipt of systemic antifungal therapy within 4 weeks prior to transplantation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittaburgh, VA Pittsburgh Health Systems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Cente</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, Meneses K, Busuttil RW, Singh N. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014 Dec;14(12):2758-64. doi: 10.1111/ajt.12963. Epub 2014 Nov 6.</citation>
    <PMID>25376267</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 15, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2009</firstreceived_date>
  <firstreceived_results_date>December 8, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Nina Singh</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Nervous System Fungal Infections</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Fungal</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anidulafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anidulafungin</title>
          <description>anti-fungal agent
Anidulafungin: 200 mg IV loading dose followed by 100 mg qd for 21 days</description>
        </group>
        <group group_id="P2">
          <title>Fluconazole</title>
          <description>anti-fungal agent
Fluconazole: 400 mg IV for 21 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anidulafungin</title>
          <description>anti-fungal agent
Anidulafungin: 200 mg IV loading dose followed by 100 mg qd for 21 days</description>
        </group>
        <group group_id="B2">
          <title>Fluconazole</title>
          <description>anti-fungal agent
Fluconazole: 400 mg IV for 21 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="100"/>
                <measurement group_id="B3" value="200"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
                <measurement group_id="B2" value="89"/>
                <measurement group_id="B3" value="178"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="58" lower_limit="52" upper_limit="62"/>
                <measurement group_id="B2" value="58" lower_limit="51" upper_limit="62"/>
                <measurement group_id="B3" value="58" lower_limit="52" upper_limit="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="61"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="67"/>
                <measurement group_id="B2" value="72"/>
                <measurement group_id="B3" value="139"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="65"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="73"/>
                <measurement group_id="B2" value="62"/>
                <measurement group_id="B3" value="135"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="100"/>
                <measurement group_id="B3" value="200"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Fungal Infection</title>
        <time_frame>90 days post enrollment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Anidulafungin</title>
            <description>anti-fungal agent
Anidulafungin: 200 mg IV loading dose followed by 100 mg qd for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>anti-fungal agent
Fluconazole: 400 mg IV for 21 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Fungal Infection</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Additional Antifungal Therapy</title>
        <time_frame>90 days post enrollment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Anidulafungin</title>
            <description>anti-fungal agent
Anidulafungin: 200 mg IV loading dose followed by 100 mg qd for 21 days</description>
          </group>
          <group group_id="O2">
            <title>Fluconazole</title>
            <description>anti-fungal agent
Fluconazole: 400 mg IV for 21 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Need for Additional Antifungal Therapy</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Anidulafungin</title>
          <description>anti-fungal agent
Anidulafungin: 200 mg IV loading dose followed by 100 mg qd for 21 days</description>
        </group>
        <group group_id="E2">
          <title>Fluconazole</title>
          <description>anti-fungal agent
Fluconazole: 400 mg IV for 21 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged QT interval</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>deaths</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Nina Singh</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412 360-1688</phone>
      <email>nis5@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
